Overview

YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Ipilimumab